Early Phase 1 N=20 Cabergoline in Metastatic Breast Cancer
Recurrent Breast Cancer · Stage IV Breast Cancer
Primary: Overall Response Rate (ORR) at 2 Months — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=122 Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Breast Cancer · Neutropenia
Primary: The Duration in Days of Grade 4 (Severe) Neutropenia Observed in Chemotherapy Cycle 1 in Comparison to Placebo — 1.3; 3.9 days
Phase 2 N=46 Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia
Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
Primary: Change in Soluble Vascular Cell Adhesion Molecule-1 (sVCAM) — -3.2; 4.17 ng/mL
N/A N=37 Fish Oil for HIV-Related Inflamm-aging and Immune Senescence
HIV Infection
Primary: Change in Markers of Immune Senescence Between Baseline Values and Values After 12 Weeks of Supplementation — 1.87; 4.22; -2.83; -1.56 percentage of cells — p=< 0.05
N/A N=13 Pilot Study of Laser Hair Depilation for Pilonidal Disease
Pilonidal Disease
Primary: Tolerability of Laser Treatment — 2 score on a scale
Phase 3 N=284 Shortening Treatment by Advancing Novel Drugs
Tuberculosis, Pulmonary, Drug Sensitive · Tuberculosis, Pulmonary, Multi Drug-resistant
Primary: Incidence of Combined Bacteriologic Failure or Relapse or Clinical Failure at Month 12 From Start of Therapy (Day 1) (Modified Intent to Treat [MITT] Population) — 38…
N/A N=34 Adjunctive Neurovascular Support for Wide-neck Aneurysm Embolization and Reconstruction
Intracranial Aneurysms
Primary: Number of Participants Who Achieved a Raymond Score I/II or Experienced Neurological Death — 0; 29 Participants
Phase 1 N=72 Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction
Neoplasms · Lymphomas
Primary: Dose Limiting Toxicity (DLTs) — 0; 0; 0; 0 Toxicities
Phase 2 N=16 Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol
Crohn's Disease
Primary: Number of Subjects Reporting at Least One Treatment-Emergent Adverse Event (TEAE) During Study Treatment (up to 303 Weeks) — 2; 6; 2 Participants
Phase 2 N=31 ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate
Rheumatoid Arthritis
Primary: Disease Activity Score 28-CRP (DAS28-CRP) at Week 4 — 5.40; 5.05 Scores on scale
N/A N=40 A Personalized Telehealth Intervention for Health and Weight Loss in Postpartum Women
Postpartum Weight Retention
Primary: Body Weight Change — -0.1; 1.8 kg
Phase 3 N=152 Effect of Phenazopyridine on Prolapse Surgery Voiding Trials
Urinary Retention Postoperative
Primary: Number of Participants With Postoperative Urinary Retention After Pelvic Organ Prolapse Surgery (INTENT-TO-TREAT) — 30; 25 Participants
Phase 4 N=939 Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea
Type 2 Diabetes Mellitus · Inadequate Glycaemic Control
Primary: Change in Haemoglobin A1c (HbA1c) From Baseline to Week 52 — -0.82; -1.2; -0.99 HbA1c % — p=0.001
Phase 3 N=21 Dane County Drug Court Study for Addicted Offenders
Opioid Dependence
Primary: Number of Participants With New Crime — 5; 3 Participants
Phase 3 N=25 VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV
Smallpox Vaccine Adverse Reaction
Primary: Percent of Participants With Adverse Events Related to ACAM2000 Vaccine Administration — 52; 8; 4 percentage of participants